! g' K c9 i0 f$ \7 g
临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究:# E X4 m1 F# \" e. Q8 X
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer. 5 q) {6 t5 h# }http://www.ncbi.nlm.nih.gov/pubmed/22968184* u, ~" G$ W! v) I* ^2 U, z